Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-APP in cerebral amyloid angiopathy
NL-OMON60283Phase 2Active, not recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Apr 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of mivelsiran in cerebral amyloid angiopathy (CAA), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Annualized rate of new lobar cerebral microbleeds. Started Apr 2025; status: active, not recruiting.
02
Drugs
mivelsiran
03
Conditions
cerebral amyloid angiopathy (CAA)
Beyond the preview
Go deeper on NL-OMON60283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60283.